Vesalius Longevity Labs Inc. — SEC Form D Filing

Vesalius Longevity Labs Inc. filed an SEC Form D on November 3, 2026, reporting $30.11M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
November 3, 2026
Amount reported
$30.11M
Round stage
Growth stage, driven by a $30.1 million equity raise and a planned public listing via a reverse-takeover transaction.
Industry
Pharmaceuticals
Website
https://www.vesaliustx.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: BRITISH COLUMBIA, CANADA

Problem

Healthcare providers and longevity clinics lack standardized access to high-quality peptide active pharmaceutical ingredients and integrated fulfillment infrastructure needed to scale preventive therapeutics.

Solution

Vesalius Longevity Labs delivers the Peptual active pharmaceutical ingredient platform alongside turnkey telehealth software and product fulfillment to enable clinics to administer advanced longevity therapeutics.

Why now

Rapidly growing consumer demand for proactive healthspan optimization combined with advancements in peptide synthesis necessitates compliant supply chains and provider enablement technologies.

Source: SEC EDGAR Form D filing